UA114277C2 - Антиангіогенна терапія для лікування раку яєчника - Google Patents

Антиангіогенна терапія для лікування раку яєчника

Info

Publication number
UA114277C2
UA114277C2 UAA201211033A UAA201211033A UA114277C2 UA 114277 C2 UA114277 C2 UA 114277C2 UA A201211033 A UAA201211033 A UA A201211033A UA A201211033 A UAA201211033 A UA A201211033A UA 114277 C2 UA114277 C2 UA 114277C2
Authority
UA
Ukraine
Prior art keywords
treatment regimen
treatment
patient
therfpy
angiogenesis
Prior art date
Application number
UAA201211033A
Other languages
English (en)
Inventor
Джейкоб ДЮПОН
Корнелія Ірль
Корнелия ИРЛЬ
Original Assignee
Дженентек, Інк.
Дженентек, Инк.
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44476669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA114277(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дженентек, Інк., Дженентек, Инк., Ф. Хоффманн-Ля Рош Аг filed Critical Дженентек, Інк.
Publication of UA114277C2 publication Critical patent/UA114277C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Theoretical Computer Science (AREA)
  • Business, Economics & Management (AREA)
  • Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід стосується способу лікування пацієнта, у якого діагностовано рецидивуючий платиночутливий епітеліальний рак яєчника, рак фаллопієвих труб або первинний рак очеревини, що включає вплив на пацієнта режимом лікування, який комбінує хіміотерапію з введенням 15 мг/кг бевацизумабу з подальшою підтримуючою терапією на основі бевацизумабу, де хіміотерапія вказаного режиму лікування включає введення карбоплатину з гемцитабіном, де вказаний режим лікування ефективно продовжує виживаність пацієнта без прогресування.
UAA201211033A 2010-02-23 2011-02-22 Антиангіогенна терапія для лікування раку яєчника UA114277C2 (uk)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30709510P 2010-02-23 2010-02-23
US35123110P 2010-06-03 2010-06-03
US36005910P 2010-06-30 2010-06-30
US201161439819P 2011-02-04 2011-02-04
PCT/US2011/025651 WO2011106300A2 (en) 2010-02-23 2011-02-22 Anti-angiogenesis therapy for the treatment of ovarian cancer

Publications (1)

Publication Number Publication Date
UA114277C2 true UA114277C2 (uk) 2017-05-25

Family

ID=44476669

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201211033A UA114277C2 (uk) 2010-02-23 2011-02-22 Антиангіогенна терапія для лікування раку яєчника

Country Status (20)

Country Link
US (8) US8778340B2 (uk)
EP (3) EP3064509A3 (uk)
JP (6) JP2013520442A (uk)
KR (4) KR20180028561A (uk)
CN (3) CN110227154A (uk)
AR (1) AR080244A1 (uk)
AU (5) AU2011221229B2 (uk)
BR (1) BR112012020700A8 (uk)
CA (2) CA2787952C (uk)
CL (1) CL2012002326A1 (uk)
CO (1) CO6592072A2 (uk)
IL (2) IL221058B (uk)
MA (1) MA34059B1 (uk)
MX (3) MX369170B (uk)
PH (2) PH12012501681A1 (uk)
RU (1) RU2012140447A (uk)
SG (2) SG10201401123VA (uk)
TW (2) TWI619509B (uk)
UA (1) UA114277C2 (uk)
WO (1) WO2011106300A2 (uk)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
JP6170496B2 (ja) 2011-09-23 2017-07-26 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用
BR112014018964A2 (pt) * 2012-03-13 2020-05-12 F. Hoffmann-La Roche Ag Anticorpo anti-vegf e uso de um anticorpo anti-vegf
EP2872534B1 (en) 2012-07-13 2018-08-08 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
SG11201500903XA (en) * 2012-08-07 2015-03-30 Genentech Inc Combination therapy for the treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
MX381141B (es) 2014-02-10 2025-03-12 Merck Patent Gmbh INHIBICIÓN DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGF ß).
UA120611C2 (uk) * 2014-04-04 2020-01-10 Тайхо Фармасьютікал Ко., Лтд. Протипухлинний засіб, який містить таксанову сполуку і підсилювач протипухлинного ефекту
SG11201609168PA (en) * 2014-05-07 2016-12-29 Medimmune Llc Methods of using anti-ang2 antibodies
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
MX2017006201A (es) * 2014-11-14 2017-07-31 Genentech Inc Respuesta de prediccion a un antagonista de vegf.
KR102700777B1 (ko) * 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
TW201713360A (en) * 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP3272771A1 (en) * 2016-07-22 2018-01-24 Centre National De La Recherche Scientifique Treatment for use for preventing metastasis in a subject exposed to cancer treatment inducing p38 activation
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
CN112165957A (zh) * 2018-03-26 2021-01-01 上海易乐生物技术有限公司 proBDNF调节剂在B细胞相关疾病中的用途
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112023018305A2 (pt) * 2021-03-10 2023-10-31 Canariabio Inc Uso de oregovomabe e bevacizumabe, paclitaxel, carboplatina para tratamento de recidiva de brca do tipo selvagem sensível à platina
CN115814076A (zh) * 2021-07-01 2023-03-21 江苏先声药业有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
EP4504260A1 (en) * 2022-04-04 2025-02-12 Merck Sharp & Dohme LLC Methods for treating cancer, an infectious disease or an infection using a combination of a tigit antagonist, a pd-1 antagonist, and a vegf antagonist

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US991302A (en) * 1910-03-28 1911-05-02 Frederick G Hepburn Waste-supporter.
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0666868B2 (en) 1992-10-28 2006-06-14 Genentech, Inc. Use of anti-VEGF antibodies for the treatment of cancer
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CN101665536B (zh) 1997-04-07 2013-07-03 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
KR100870353B1 (ko) 1997-04-07 2008-11-25 제넨테크, 인크. 항-ｖｅｇｆ 항체
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
ES2270893T3 (es) 1999-12-24 2007-04-16 Genentech, Inc. Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR20160014775A (ko) * 2003-05-30 2016-02-11 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
HUE058817T2 (hu) 2004-09-03 2022-09-28 Genentech Inc Humanizált anti-béta7 antagonisták és alkalmazásaik
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
BRPI0817182A2 (pt) * 2007-10-30 2015-03-17 Genentech Inc Método para purificar um anticorpo e composições
AR074203A1 (es) 2008-11-22 2010-12-29 Genentech Inc Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso.

Also Published As

Publication number Publication date
JP2013173775A (ja) 2013-09-05
KR20180135101A (ko) 2018-12-19
IL221058B (en) 2018-04-30
US20160279241A1 (en) 2016-09-29
SG183414A1 (en) 2012-09-27
PH12016501728A1 (en) 2018-02-12
EP3696194A1 (en) 2020-08-19
MA34059B1 (fr) 2013-03-05
AU2015210479A1 (en) 2015-09-03
EP3064509A3 (en) 2016-11-02
MX369170B (es) 2019-10-30
AU2017204320B2 (en) 2019-02-21
CA2787952C (en) 2016-07-26
IL258612A (en) 2018-06-28
CA2787952A1 (en) 2011-09-01
AU2011221229B2 (en) 2015-06-18
US20210052728A1 (en) 2021-02-25
CN103237810A (zh) 2013-08-07
US20170143826A1 (en) 2017-05-25
US20250177522A1 (en) 2025-06-05
EP2539367A2 (en) 2013-01-02
KR102104197B1 (ko) 2020-04-24
US20230226179A1 (en) 2023-07-20
TWI457135B (zh) 2014-10-21
SG10201401123VA (en) 2014-08-28
JP2016020354A (ja) 2016-02-04
RU2012140447A (ru) 2014-03-27
US20180344847A1 (en) 2018-12-06
AR080244A1 (es) 2012-03-21
TWI619509B (zh) 2018-04-01
KR102104197B9 (ko) 2022-10-21
CA2930248A1 (en) 2011-09-01
KR20130010884A (ko) 2013-01-29
AU2019210484A1 (en) 2019-08-15
MX2019000425A (es) 2023-04-27
BR112012020700A8 (pt) 2018-01-02
US8778340B2 (en) 2014-07-15
AU2011221229A1 (en) 2012-08-16
MX2012009554A (es) 2012-11-23
TW201138819A (en) 2011-11-16
WO2011106300A2 (en) 2011-09-01
JP2013520442A (ja) 2013-06-06
JP2020196719A (ja) 2020-12-10
PH12012501681A1 (en) 2012-11-05
EP3064509A2 (en) 2016-09-07
JP2017193551A (ja) 2017-10-26
TW201526912A (zh) 2015-07-16
JP2018199683A (ja) 2018-12-20
AU2019203466A1 (en) 2019-06-06
BR112012020700A2 (pt) 2017-03-21
KR101839161B1 (ko) 2018-03-16
AU2017204320A1 (en) 2017-07-13
WO2011106300A3 (en) 2011-12-15
CN120733043A (zh) 2025-10-03
JP6184733B2 (ja) 2017-08-23
CO6592072A2 (es) 2013-01-02
US20140178371A1 (en) 2014-06-26
IL258612B (en) 2022-01-01
KR20190143480A (ko) 2019-12-30
US20110206662A1 (en) 2011-08-25
KR101839161B9 (ko) 2022-10-18
CL2012002326A1 (es) 2012-11-30
KR20180028561A (ko) 2018-03-16
CN110227154A (zh) 2019-09-13

Similar Documents

Publication Publication Date Title
UA114277C2 (uk) Антиангіогенна терапія для лікування раку яєчника
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
MX361218B (es) Análogos de spliceostatina.
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
CY1120516T1 (el) Θεραπειες για τον καρκινο
MD20170046A2 (ro) Metode pentru tratamentul infecţiilor virale cu Filoviridae
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MX370818B (es) Anticuerpos anti-b7-h1 para tratar tumores.
UA118025C2 (uk) Модулятор андрогенних рецепторів і його застосування
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
EA201892769A3 (ru) Сложные диэфиры ациклических нуклеозидфосфонатов
EP4570314A3 (en) Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
PE20141909A1 (es) Terapia combinada para el tratamiento del cancer de ovario
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
CY1123044T1 (el) Νεες ενωσεις
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
PH12017501881A1 (en) Methods for treating cancer
EA202091218A1 (ru) Соли дифосфатфосфорамидата нуклеозидов в качестве противораковых соединений
MX2016006927A (es) Compuesto de la familia de la avermectina o de la familia de la milbemicina para el tratamiento y/o la prevencion de la dermatitis atopica.
EA201401045A1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
RU2014106575A (ru) Способ профилактики кровотечения при миомэктомии
EA202192660A1 (ru) Противораковые соединения
MX2014014821A (es) Biomarcadores de plasma sanguineo para terapias de combinacion con bevacizumab para el tratamiento de cancer de mama.